Coherus BioSciences (CHRS) Misses Q1 EPS by 7c, provides R&D and SG&A expense guidance

Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.32), $0.07 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $77.1 million versus the consensus estimate of $81.7 million.

2024 R&D and SG&A Expense Guidance
Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million. This guidance includes approximately $40 million of stock-based compensation expense and excludes the effects of acquisitions, collaborations, investments, divestitures including expenses incurred on behalf of and reimbursed by Sandoz to satisfy Coherus’ obligations under the Transition Services Agreement (TSA), restructuring, the exercise of rights or options related to collaboration programs, and any other transactions or circumstances not yet identified or quantified. This guidance is subject to a number of risks and uncertainties.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Jefferies upgrades Five Below to buy, sees path to TJX-like re-rating
• Omega Flex (OFLX) Tops Q2 EPS by 27c
• Ackman adds Netflix, Visa and Mastercard in portfolio revamp